Progressive or Recurrent Glioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Progressive or Recurrent Glioma Market Outlook

Thelansis’s “Progressive or Recurrent Glioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive or Recurrent Glioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Progressive or Recurrent Glioma Overview

Glioblastoma (GBM) represents the most common and aggressive primary malignant tumor of the central nervous system in adults. Standard treatment for newly diagnosed GBM typically involves maximal safe surgical resection, followed by a combination of radiotherapy and temozolomide (TMZ) chemotherapy and subsequent six cycles of adjuvant TMZ. Despite this aggressive approach, the median overall survival (OS) for patients with GBM remains poor, ranging from 12 to 18 months, with a 5-year survival rate of less than 7%. Prognostic factors in GBM include patient age and performance status at diagnosis. Younger patients and those with a good performance status—defined by a Karnofsky Performance Score (KPS) greater than 70 or a World Health Organization (WHO) performance status of 0—tend to have better outcomes. Unfortunately, GBM almost invariably recurs after initial treatment, leading to a significantly diminished prognosis. The median progression-free survival (PFS) for recurrent or progressive glioma is only 1.5 to 6 months, while the median OS after recurrence is between 2 and 9 months. Treatment options for recurrent GBM are limited, and effective management remains a significant clinical challenge. Therapeutic strategies for recurrent GBM may include repeat surgery, re-irradiation, and chemotherapy (e.g., bevacizumab, lomustine).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: